Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Loss of Specific MicroRNA Spurs Drug Resistance in Breast Cancer Cells

By BiotechDaily International staff writers
Posted on 17 May 2012
A study determined that development of resistance to the chemotherapeutic drug tamoxifen by breast tumors was due to the disappearance of a specific microRNA.

MicroRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

In the study, investigators at the German Cancer Research Center (Heidelberg, Germany) related genome-wide miRNA microarray analyses of breast tumors to the appearance in the tumors of resistance to tazmoxifen.

They reported in the April 16, 2012, online edition of the journal Oncogene that the microRNA miRNA-375 was among the top downregulated miRNAs in resistant cells. Reexpression of miR-375 was sufficient to resensitize tumor cells to tamoxifen and partly reversed the epithelial–mesenchymal transition (EMT), which is characteristic of tumor cells.

A combination of mRNA profiling, bioinformatics analysis, and experimental validation identified the protein metadherin (MTDH) as a direct target of miR-375. Metadherin is an oncogenic protein that is normally blocked by miR-375. The importance of MTDH was confirmed in experiments with tumor cells that lacked the MTDH gene. In these tumors, even in the absence of miR-375, no resistance to tamoxifen arose.

“The analysis of microRNAs in breast cancer has put us on the track of metadherin. We will possibly be able to specifically influence the cancer-promoting properties of this protein in the future,” said coauthor Dr. Stefan Wiemann, associate professor of molecular genome analysis at the German Cancer Research Center. “Resistances to drugs are the main reason why therapies fail and disease progresses in many cancers. We want to understand what goes on in the cells when this happens so we can develop better therapies in the future.”

Related Links:

German Cancer Research Center



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.